Equities

Bellevue Life Sciences Acquisition Corp

BLAC:NAQ

Bellevue Life Sciences Acquisition Corp

Actions
FinancialsOpen End and Miscellaneous Investment Vehicles
  • Price (USD)10.80
  • Today's Change-0.01 / -0.09%
  • Shares traded5.64k
  • 1 Year change+5.26%
  • Beta--
Data delayed at least 15 minutes, as of Jul 03 2024 17:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bellevue Life Sciences Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company has not selected any business combination target, and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company may pursue an acquisition opportunity in any business industry or sector. The Company intends to acquire and manage a business in the healthcare industry, more specifically in the biotechnology sector. The Company neither engaged in any operations nor generated any revenues.

  • Revenue in USD (TTM)0.00
  • Net income in USD233.04k
  • Incorporated2020
  • Employees--
  • Location
    Bellevue Life Sciences Acquisition Corp10900 Ne 4Th Street, Suite 2300BELLEVUE 98004United StatesUSA
  • Phone+1 (425) 635-7700
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BLAC:NAQ since
announced
Transaction
value
OSR Holdings LtdAnnounced11 Jul 202311 Jul 2023Announced5.26%--
Data delayed at least 15 minutes, as of Jul 03 2024 17:30 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AIB Acquisition Corp0.00-1.12m41.65m----7.17-----0.3106-0.31060.001.610.00-------9.85---14.11--------------0.1654-------224.63------
DMY Squared Technology Group Inc0.001.60m42.00m--58.752.18----0.18250.18250.004.920.00------3.49--3.64--------------0.0558------196.18------
Yotta Acquisition Corp0.001.32m43.35m2.0053.78------0.20430.20430.00-0.00630.00----0.002.07--2.20--------------1.01------884.52------
DUET Acquisition Corp0.00129.69k43.58m--265.636.89----0.04190.04190.001.620.00------0.2494--0.2673--------------0.2859------147.44------
Enterprise Diversified Inc3.72m110.89k43.62m6.00191.891.29379.5311.710.04170.04171.416.180.2167--43.91620,561.700.64531.100.67461.1786.2770.022.983.59---86.400.00--12.473.48-9.37------
Bellevue Life Sciences Acquisition Corp0.00233.04k43.65m--552.711.87----0.01950.01950.005.770.00------0.4302--0.4431--------------0.0041------1,240.94------
Moringa Acquisition Corp0.00-250.34k43.81m0.00--16.541,188.19---0.0843-0.08430.000.68450.00-------1.53---1.81--------------0.00-------54.96------
PMV Consumer Acquisition Corp0.00-86.93k43.88m0.00---------0.8691-0.86910.005.440.00-------6.98---13.11--------------0.00-------101.25------
Kairous Acquisition Corp Ltd0.00232.70k44.39m--218.614.33190.77--0.05510.05510.002.780.00------1.21--1.36--------------0.1974------630.08------
Integral Acquisition Corp 10.00816.49k44.73m--51.484.75----0.21330.21330.002.310.00------1.23--1.27--------------0.1529------205.91------
Bannix Acquisition Corp0.00-273.77k44.90m----3.49-----0.0502-0.05020.003.150.00-------1.13---1.31--------------0.0724-------220.65------
Fintech Ecosystem Development Corp0.001.78m45.24m0.00110.272.2625.44--0.10330.10330.005.030.00------2.24--2.29--------------0.02------303.82------
Panamera Holdings Corp25.00k-14.72m45.41m----6.10--1,816.22-0.378-0.37790.00060.16390.0066--6.00---389.31-8,881.26-399.36--16.60---58,866.04-5,163.75---5,273.740.0097--139.98---20,830.26------
ACRI Capital Acquisition Corp0.00625.36k45.63m--100.961.94----0.11380.11380.005.930.00------1.64--1.73--------------0.0608------308.05------
Nuveen New Yrk Slct Tx Fr ncm Prtfl-100.00bn-100.00bn45.88m--------------------------------------------------9.29--176.65------
Data as of Jul 03 2024. Currency figures normalised to Bellevue Life Sciences Acquisition Corp's reporting currency: US Dollar USD

Institutional shareholders

45.65%Per cent of shares held by top holders
HolderShares% Held
TD Securities (USA) LLCas of 31 Mar 2024369.85k6.58%
W.R. Berkley Corp. (Investment Portfolio)as of 31 Mar 2024322.69k5.74%
Wolverine Asset Management LLCas of 31 Mar 2024291.51k5.18%
Walleye Capital LLCas of 31 Mar 2024262.70k4.67%
Polar Asset Management Partners, Inc.as of 31 Mar 2024260.00k4.62%
AQR Arbitrage LLCas of 31 Mar 2024250.00k4.45%
RiverNorth Capital Management LLCas of 31 Mar 2024245.12k4.36%
Fir Tree Capital Management LPas of 31 Mar 2024214.86k3.82%
Exos Asset Management LLCas of 31 Mar 2024200.00k3.56%
Periscope Capital, Inc.as of 31 Mar 2024150.00k2.67%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.